1. Home
  2. WEC vs INSM Comparison

WEC vs INSM Comparison

Compare WEC & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo WEC Energy Group Inc.

WEC

WEC Energy Group Inc.

HOLD

Current Price

$114.14

Market Cap

35.3B

Sector

Utilities

ML Signal

HOLD

Logo Insmed Incorporated

INSM

Insmed Incorporated

HOLD

Current Price

$164.56

Market Cap

31.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WEC
INSM
Founded
1896
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Power Generation
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
35.3B
31.2B
IPO Year
1995
2000

Fundamental Metrics

Financial Performance
Metric
WEC
INSM
Price
$114.14
$164.56
Analyst Decision
Buy
Strong Buy
Analyst Count
12
23
Target Price
$118.42
$191.09
AVG Volume (30 Days)
2.5M
2.1M
Earning Date
05-04-2026
05-21-2026
Dividend Yield
3.34%
N/A
EPS Growth
N/A
N/A
EPS
4.81
N/A
Revenue
$9,800,100,000.00
N/A
Revenue This Year
$6.05
$130.70
Revenue Next Year
$6.51
$74.05
P/E Ratio
$23.67
N/A
Revenue Growth
13.96
N/A
52 Week Low
$100.64
$60.40
52 Week High
$118.19
$212.75

Technical Indicators

Market Signals
Indicator
WEC
INSM
Relative Strength Index (RSI) 64.15 56.08
Support Level $113.34 $147.26
Resistance Level $117.35 $151.17
Average True Range (ATR) 2.31 6.12
MACD 0.11 2.05
Stochastic Oscillator 65.01 95.82

Price Performance

Historical Comparison
WEC
INSM

About WEC WEC Energy Group Inc.

WEC Energy Group's electric and gas utility businesses serve electric and gas customers in Illinois, Michigan, Minnesota, and Wisconsin service territories. The company also owns a 60% stake in American Transmission Co. WEC's asset mix is approximately 49% electric generation and distribution, 32% gas distribution, 10% electric transmission, 7% unregulated renewable energy, and 2% LNG distribution and generation.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

Share on Social Networks: